Literature DB >> 30640149

Opioid and sedative misuse among veterans wounded in combat.

Michelle L Kelley1, Adrian J Bravo2, Victoria R Votaw2, Elena Stein3, Jason C Redman4, Katie Witkiewitz3.   

Abstract

BACKGROUND: Military veterans wounded in combat are a high-risk group for emotional and physical distress, which may be exacerbated by misuse of prescription opioids and sedatives. The goal of the current study was to examine the prevalence and correlates of prescription opioid and sedative misuse among veterans wounded in combat.
METHOD: We recruited veterans from the Combat Wounded Coalition (n = 212; 84% non-Hispanic White; 97.6% male) to complete an online survey of mental health and substance use disorder symptoms, assessed via the DSM-5 Self-Rated Level 1 Cross-Cutting Symptoms Measure, the Posttraumatic Stress Disorder (PTSD) Checklist for DSM-5, the Pain Enjoyment General Activity Scale, and the Alcohol Use Disorders Identification Test (AUDIT). Prescription opioid and sedative misuse was assessed by frequency of use in the past year that was not currently prescribed or using more than prescribed.
RESULTS: Participants reported high rates of past year prescription opioid misuse (46.2%) and sedative misuse (21.7%). Misuse of both opioids and sedatives was associated with the most distress, including greater depression, anger, sleep disturbance, AUDIT scores, PTSD symptoms, suicidality, and pain interference. In multivariable multinomial logistic regression analyses, greater sleep disturbance (OR = 1.73) was associated with greater odds of sedative misuse versus no misuse. Higher AUDIT scores were associated with greater risk of sedative misuse (OR = 1.16) versus opioid misuse only.
CONCLUSIONS: Military veterans wounded in combat have high rates of prescription opioid misuse and sedative misuse. Sleep problems and AUDIT scores might help identify veterans who are at most risk for opioid and sedative misuse.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Mental health; Opioid misuse; Sedative misuse; Substance use disorders; Wounded veterans

Year:  2018        PMID: 30640149     DOI: 10.1016/j.addbeh.2018.12.007

Source DB:  PubMed          Journal:  Addict Behav        ISSN: 0306-4603            Impact factor:   3.913


  6 in total

1.  Therapeutic relationships between Veterans and buprenorphine providers and effects on treatment retention.

Authors:  Jayamalathi Priyanka Vakkalanka; Brian C Lund; Stephan Arndt; William Field; Mary Charlton; Marcia M Ward; Ryan M Carnahan
Journal:  Health Serv Res       Date:  2021-12-18       Impact factor: 3.734

Review 2.  Health harms of non-medical prescription opioid use: A systematic review.

Authors:  Dan Werb; Ayden I Scheim; Ayorinde Soipe; Samantha Aeby; Indhu Rammohan; Benedikt Fischer; Scott E Hadland; Brandon D L Marshall
Journal:  Drug Alcohol Rev       Date:  2022-04-18

3.  Association Between Buprenorphine for Opioid Use Disorder and Mortality Risk.

Authors:  Priyanka Vakkalanka; Brian C Lund; Stephan Arndt; William Field; Mary Charlton; Marcia M Ward; Ryan M Carnahan
Journal:  Am J Prev Med       Date:  2021-05-19       Impact factor: 5.043

4.  Sedative/Tranquilizer Misuse is Associated With Alcohol and Illicit Drug Problems, Mental Health Issues, and Impulsivity and Compulsivity in University Students.

Authors:  Jon E Grant; Katherine Lust; Samuel R Chamberlain
Journal:  J Addict Med       Date:  2020 May/Jun       Impact factor: 4.647

5.  Erector spinae plane block for affective and safe analgesia in a patient with severe penetrating chest trauma caused by an explosion in the battlefield.

Authors:  Dmytro Dmytriiev; Dan Sebastian Dîrzu; Mykola Melnychenko; Rudiger Eichholz
Journal:  Clin Case Rep       Date:  2022-10-08

6.  A comprehensive multivariate model of biopsychosocial factors associated with opioid misuse and use disorder in a 2017-2018 United States national survey.

Authors:  Francisco A Montiel Ishino; Philip R McNab; Tamika Gilreath; Bonita Salmeron; Faustine Williams
Journal:  BMC Public Health       Date:  2020-11-18       Impact factor: 3.295

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.